Efectiveness of doxazosin in systemic hyperftension

Richard P. Ames, Steven G. Chrysant, Francisco Gonzalez, Harold W. Schnaper, Stephan Spann, Manuel T. Velasquez

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Most α-receptor blocking drugs require divided daily administration because of a short plasma half-life. This mutticenter study examined the effectiveness and safety of once-daily administration with doxazosin, a quinazofine analog ai-receptor blocking drug with a plasma half-life of 19 hours. Patients with diastolic blood pressure (BP) of 90 to 115 mm Hg entered 4 weeks of single-blind placebo therapy and then were randomized to doubleblind treatment with doxazosin (63 patients) or placebo (67 patients). After 10 weeks of titration, standing arterial BP was lowered by 14/11 mm Hg with doxazosin and by 0.5/0.9 mm Hg with placebo (p < 0.001). Measured hourly for 12 hours after the dose, all standing and supine arterial BP values were significantly lower in the doxazosin group at each hour. Pulse rate increased slightly in both groups in the double-blind phase, but the increase with doxazosin never significantly exceeded that of placebo. Dizziness was the most common complaint with doxazosin, but syncope did not occur. Side effects were mild and transient and did not necessitate withdrawing any participants from the study. Body weight increased by 1.5 kg in the doxazosin group and decreased by 0.2 kg in the placebo group (p < 0.01). Safe and effective in once-daily administration, doxazosin is suitable for initial therapy in mild and moderate hypertension.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalAmerican Journal of Cardiology
Issue number3
StatePublished - 15 Jul 1989
Externally publishedYes


Dive into the research topics of 'Efectiveness of doxazosin in systemic hyperftension'. Together they form a unique fingerprint.

Cite this